Differences in the management of early and established rheumatoid arthritis;Diferencias en el manejo de la artritis reumatoide precoz y establecida

Reumatologia Clinica

Volumn 7, Issue 3, 2011, Pages 172-178

  Castañeda, Santos ^a   Navarro, Federico ^b   Fernández Carballido, Cristina ^c   Tornero, Carmelo ^d   Marced, Elena ^e   Corteguera, Montserrat ^f  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^c Hospital de Elda   (Spain)

^d HOSPITAL MORALES MESEGUER   (Spain)

^e AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^f HOSPITAL NUESTRA SEÑORA DE SONSOLES   (Spain)

Author keywords

Clinical control; Disease modifying anti rheumatic drugs; Early arthritis; Rheumatoid arthritis; TNF blocking drugs

Indexed keywords

ADALIMUMAB; DEFLAZACORT; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INDOMETACIN; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; CLINICAL FEATURE; DEMOGRAPHY; DISEASE ACTIVITY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; SPAIN; TREATMENT OUTCOME;

EID: 79953803426     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2010.08.001     Document Type: Article

References (29)

1. Lozano JA. Artritis reumatoide (I). Etiopatogenia, sintomatología, diagnóstico y pronóstico. [Accedido 8 Jun 2010]. Disponible en: http://external.doyma.es/pdf/4/4v20n08a13018371pdf001.pdf.
2. Carmona L., Gabriel R., Ballina F.J., Laffon A. Proyecto EPISER 2000: prevalencia de enfermedades reumáticas en la población española. Metodología, resultados del reclutamiento y características de la población. Rev Esp Reumatol. 2001, 28:18-25. Grupo de Estudio EPISER.
3. Carmona L., Villaverde V., Hernández C., Ballina J., Gabriel R., Laffon A. The prevalence of rheumatoid arthritis in the general population of Spain. Rheumatology (Oxford). 2002, 41:88-95. the EPISER Study Group.
4. Lajas C., Abásolo L., Bellajdel B., Hernández-García C., Carmona L., Vargas E., et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum. 2003, 49:64-70.
5. Reginster J.Y. The prevalence and burden of arthritis. Rheumatology (Oxford). 2002, 41(Suppl 1):3-6.
6. Domínguez A. Costes asociados a la artritis reumatoide. Rev Esp Econ Salud. 2003, 2:212-217.
7. Guía de Práctica Clínica para el Manejo de la Artritis Reumatoide (GUIPCAR) en España. Marzo de 2007. [Accedido 8 Jun 2010]. Disponible en: http://www.ser.es/practicaClinica/GUIPCAR_2007/Metodologia/Menu1_Metodologia.php.
8. Schwartzman S., Fleischmann R., Morgan J. Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?. Arthritis Res Ther. 2004, 6(Suppl 2):S3-11.
9. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum. 2002, 46:328-346. American College of Rheumatology subcommittee on rheumatoid arthritis guidelines.
10. Tornero Molina J., Sanmartí Sala R., Rodríguez Valverde V., Martín Mola E., Marenco de la Fuente J.L., González Álvaro I., et al. Actualización del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide. Reumatol Clin. 2010, 6:23-36.
11. Van Gestel A.M., Prevoo M.L., Vanót Hof M.A., Van Rijswijk M.H., Van de Putte L.B., Van Riel P.L. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996, 39:34-40.
12. Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. National Institute for Clinical Excellence. Technology appraisal guidance No. 36. [Accedido 8 Jun 2010]. Disponible en: http://www.nice.org.uk/.
13. Verstappen S.M., Jacobs J.W., Van der Veen M.J., Heurkens A.H., Schenk Y., Ter Borg E.J., et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007, 66:1443-1449. on behalf of the Utrecht Rheumatoid Arthritis Cohort Study group.
14. Sanders M. A review of controlled clinical trials examining the effects of antimalarial compounds and gold compounds on radiographic progression in rheumatoid arthritis. J Rheumatol. 2000, 27:523-529.
15. Ten Wolde S., Breedveld F.C., Hermans J., Vandenbroucke J.P., Van de Laar M.A., Markusse H.M., et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet. 1996, 347:347-352.
16. Klinkhoff A. Biological agents for rheumatoid arthritis: targeting both physical function and structural damage. Drugs. 2004, 64:1267-1283.
17. Furst D.E., Keystone E.C., Fleischmann R., Mease P., Breedveld F.C., Smolen J.S., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis. 2010, 69(Suppl.I):i2-29.
18. Ledingham J., Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford). 2005, 44:157-163. on behalf of the British Society for Rheumatology Standards, Guidelines and Audit Working Group (SGAWG).
19. Lee S.J., Chang H., Yazici Y., Greenberg J.D., Kremer J.M., Kavanaugh A. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study. J Rheumatol. 2009, 36:1611-1617.
20. Van der Heijde D.M., Vanót Hof M., Van Riel P.L., Van der Puttle L.B. Development of a disease activity score based on judgement in clinical practice by rheumatologists. J Rheumatol. 1993, 20:579-581.
21. Scott D.L., Kingsley G.H. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med. 2006, 355:704-712.
22. Ikeda K., Cox S., Emery P. Biological therapy in early arthritis - overtreatment or the way to go?. Arthritis Res Ther. 2007, 9:211-217.
23. Emery P., Breedveld F.C., Hall S., Durez P., Chang D.J., Robertson D., et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008, 372:375-382.
24. Emery P., Breedveld F., Van der Heijde D., Ferraccioli G., Dougados M., Robertson D., et al. Clinical remission and inhibition of radiographic progression with combination etanercept-methotrexate therapy versus monotherapy in active, early rheumatoid arthritis: 2-year results from the COMET trial. Ann Rheum Dis. 2009, 68(Suppl 3):119.
25. Allaart C.F., Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Breedveld F.C., Dijkmans B.A. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study. Clin Exp Rheumatol. 2006, 24(Suppl 43):S77-82. FARR study group.
26. Grigor C., Capell H., Stirling A., McMahon A.D., Lock P., Vallance R., et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004, 364:263-269.
27. Bakker M.F., Jacobs J.W., Verstappen S.M., Bijlsma J.W. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis. 2007, 66(Suppl 3):56-60.
28. Ward M.M. Interpreting measurements of physical function in clinical trials. Ann Rheum Dis. 2007, 66(Suppl 3):32-34.
29. Prevoo M.L., Van't Hof M.A., Kuper H.H., Van Leeuwen M.A., Van de Putte L.B., Van Riel P.L. Modified disease activity scores that include twenty-eight-joint counts. Arthritis Rheum. 1995, 38:44-48.